CARVOLIX
Research CARVOLIX (CVX.PA) on Bullrun: market cap EUR 334.81M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerCVX.PA
- ExchangeXPAR
- CountryFrance
- SectorHealthcare
- IndustryMedical Devices
- CurrencyEUR
- Market capEUR 334.81M
- Financial periodFY2025
- RevenueEUR 0
- Revenue growth-100.0%
- Net income-EUR 24.97M
- Free cash flow-EUR 11.67M
Valuation Snapshot
latest market cap is EUR 334.81M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | EUR 0 | -EUR 24.97M | -EUR 11.67M | n/a | -0.63 | EUR 1.75M | EUR 22.94M | EUR 5.76M |
| FY2024 | EUR 4.12M | -EUR 14.74M | -EUR 11.47M | 20.8% | -0.38 | EUR 1.23M | EUR 16.33M | EUR 30.27M |
| FY2023 | EUR 0 | -EUR 15.65M | -EUR 12.24M | n/a | -0.51 | EUR 1.66M | EUR 16.84M | EUR 31.53M |
| FY2022 | EUR 0 | -EUR 15.23M | -EUR 11.23M | n/a | -0.81 | EUR 2.58M | EUR 17.74M | EUR 33.83M |
| FY2021 | EUR 0 | -EUR 14.82M | -EUR 12.70M | n/a | -0.88 | EUR 11.41M | EUR 19.75M | EUR 43.54M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-10-10 | EUR 334.81M | n/a | n/a | 0 |
Dividend history
Latest trailing dividend snapshot: annual dividend/share 0 EUR.
About CARVOLIX
Carvolix SA, a medical technology company, develops and markets minimally invasive, minimally invasive medical devices in the field of urology and structural heart in France. It offers Artus, an implantable electro-mechanical artificial sphincter that targets moderate to severe urinary incontinence; and Kalios and Epygon implants for the treatment of mitral insufficiency, as well as Kardiozis technology for treating abdominal aortic aneurysm.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is CARVOLIX's market cap?
CARVOLIX's market capitalization is EUR 334.81M.
What does CARVOLIX do?
Carvolix SA, a medical technology company, develops and markets minimally invasive, minimally invasive medical devices in the field of urology and structural heart in France. It offers Artus, an implantable electro-mechanical artificial sphincter that targets moderate to severe urinary incontinence; and Kalios and Epygon implants for the treatment of mitral insufficiency, as well as Kardiozis technology for treating abdominal aortic aneurysm.